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Monitoring the South African National Antiretroviral 
Treatment Programme, 2003 - 2007: The IeDEA Southern 
Africa collaboration
Morna Cornell, Karl Technau, Lara Fairall, Robin Wood, Harry Moultrie, Gilles van Cutsem, Janet Giddy, Lerato Mohapi, Brian 
Eley, Patrick MacPhail, Hans Prozesky, Helena Rabie, Mary-Ann Davies, Nicola Maxwell, Andrew Boulle, for the International 
epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration
The World Health Organization (WHO) estimated that in 2007, 
9.7 million people in low- and middle-income countries needed 
antiretroviral treatment (ART),1 9% of whom were living in 
South Africa.2 By the end of 2007, the South African National 
Department of Health (DoH) reported that 371 731 people had 
initiated highly active antiretroviral therapy (HAART),2 making 
it the largest ART programme in the world.1 As the public 
health system has only provided ART since 2004, this has 
involved a massive scale-up of services within a comparatively 
short space of time.
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Objectives. To introduce the combined South African cohorts 
of the International epidemiologic Databases to Evaluate 
AIDS Southern Africa (IeDEA-SA) collaboration as reflecting 
the South African national antiretroviral treatment (ART) 
programme; to characterise patients accessing these services; 
and to describe changes in services and patients from 2003 to 
2007.
Design and setting. Multi-cohort study of 11 ART programmes 
in Gauteng, Western Cape, Free State and KwaZulu-Natal. 
Subjects. Adults and children (<16 years old) who initiated 
ART with ≥3 antiretroviral drugs before 2008.
Results. Most sites were offering free treatment to adults 
and children in the public sector, ranging from 264 to 17 835 
patients per site. Among 45 383 adults and 6 198 children 
combined, median age (interquartile range) was 35.0 years 
(29.8 - 41.4) and 42.5 months (14.7 - 82.5), respectively. Of 
adults, 68% were female. The median CD4 cell count was 
102 cells/µl (44 - 164) and was lower among males than 
females (86, 34 - 150 v. 110, 50 - 169, p<0.001). Median CD4% 
among children was 12% (7 - 17.7). Between 2003 and 2007, 
enrolment increased 11-fold in adults and 3-fold in children. 
Median CD4 count at enrolment increased for all adults 
(67 - 111 cells/µl, p<0.001) and for those in stage IV (39 - 89 
cells/µl, p<0.001). Among children <5 years, baseline CD4% 
increased over time (11.5 - 16.0%, p<0.001).
Conclusions. IeDEA-SA provides a unique opportunity to 
report on the national ART programme. The study describes 
dramatically increased enrolment over time. Late diagnosis 
and ART initiation, especially of men and children, need 
attention. Investment in sentinel sites will ensure good 
individual-level data while freeing most sites to continue with 
simplified reporting.
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In the context of such an ambitious undertaking, trends in 
enrolment and key outcomes must be understood in order to 
plan for the changing needs of health services and patients.1 
Monitoring is a major challenge to effective delivery of ART at 
a national level,2 and it becomes increasingly important as the 
continued scale-up of ART creates a tension between service 
provision and collecting good data.
The International epidemiologic Databases to Evaluate 
AIDS (IeDEA) Southern Africa (IeDEA-SA) collaboration has 
assembled a collaborative individualised dataset of children 
and adults starting ART at sites in South Africa. Numerically 
the collaboration represents 20% of all children and 10% of 
all adults entering the public sector roll-out programme. 
This provides a unique opportunity to report in detail, based 
on individual patient data, on a subset of the national ART 
programme.
This paper aims to introduce the South African cohorts 
participating in IeDEA as a collaboration that reflects the South 
African national ART programme, to characterise the children 
and adults accessing these services, and to describe changes in 
services and patients over the past 5 years.
Background and setting
The IeDEA collaboration
IeDEA is an international collaboration of seven regional data 
centres funded by the National Institutes of Health (NIH). 
It was established to pool data across numerous cohorts of 
patients on ART, creating large datasets to address research 
questions that cannot be answered within single cohorts.
IeDEA Southern Africa 
IeDEA-SA is the regional cohort collaboration of southern 
Africa. Since its establishment in 2006, 22 sites have joined 
the collaboration. The current database includes cohorts 
from South Africa, Zimbabwe, Mozambique, Zambia, 
Malawi and Botswana. Some countries have more than one 
cohort participating, providing an opportunity to describe 
characteristics and outcomes at a national level, in the absence 
of good routine national monitoring systems. In South Africa, 
11 large sites from 4 provinces have joined the collaboration.
The South African ART programme
Since the start of the national ART roll-out programme in 
2004, the South African guidelines for initiation of ART3 have 
recommended treatment for adults with CD4 cell counts <200 
cells/µl or WHO stage IV illness except for extrapulmonary 
tuberculosis, who are assessed to be willing and ready to 
take and adhere to ART. Before this, most sites offering ART 
followed similar criteria, based on the 2002 WHO guidelines.4 
First-line therapy in ART-naïve adults, unless contraindicated, 
is stavudine (d4T), lamivudine (3TC) and efavirenz (EFV) 
or nevirapine (NVP). Women of child-bearing age who are 
unable to guarantee reliable contraception should receive NVP 
instead of EFV. Patients receive monthly medication and are 
seen by a doctor at 4, 8 and 12 weeks and 3-monthly thereafter 
if well. CD4 count and viral load are measured 6-monthly. 
Patients with a detectable viral load (>400 copies/µl) receive a 
stepped-up adherence package. If their viral load persistently 
exceeds 5 000 copies/µl despite adherence support, they 
may be switched to second-line therapy. Second-line therapy 
comprises zidovudine (AZT), didanosine (ddI) and lopinavir/
ritonavir (LPV/r). Drug substitutions are also made if patients 
experience toxicity on first-line therapy.
The 2004 South African paediatric guidelines3 recommend 
ART initiation based on a confirmed HIV diagnosis (HIV 
DNA polymerase chain reaction (PCR) testing if the child 
is <18 months of age) and one of the following criteria: (i) 
recurrent hospitalisations (>2 admissions/year) or prolonged 
hospitalisation (>4 weeks) for HIV-related illness; (ii) WHO 
stage III/IV disease; or (iii) CD4 <20% if under 18 months or 
<15% for older children. Based on the  new WHO staging,5 
most paediatric sites changed from the 3- to the 4-stage system 
towards the end of 2004, which may have impacted to some 
extent on the paediatric staging data in this dataset. Paediatric 
first-line ART for children from 6 months to 3 years is d4T, 3TC 
and LPV/r. For children >3 years and >10 kg, EFV replaces 
LPV/r.
Methods
Study population
Most participating ‘sites’ comprise single clinics in urban 
or peri-urban areas. The definition of site is broad: one site 
encompasses 3 clinics, and another includes all the facilities 
within an entire province, from primary to tertiary level. The 
study included data on all adults and children (<16 years old) 
with documented age, gender and ART start date who initiated 
ART with at least 3 antiretrovirals before 2008.
Data collection and management
The study utilised data that are routinely collected by sites. All 
sites have current ethics committee approval for contribution 
of their data to IeDEA analyses. The data were all anonymised 
before transfer to the data centre. Sites submitted data during 
the course of 2007 and early 2008. Data on programme-
level characteristics were collected through site assessment 
questionnaires. 
Data analysis
Cleaning, coding and analysis of data were done in Intercooled 
STATA 10.0 for Windows (STATA Corporation, College Station, 
TX). Continuous variables were described by medians and 
interquartile ranges and categorical variables as proportions. 
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Temporal trends were tested using the Kruskal-Wallis test 
(continuous variables) and the chi-square test (categorical 
variables).
Results
Programme-level characteristics
Seven of the sites offer services to children and adults, either 
in separate or combined clinics (Table I); 1 site treats children 
and pregnant women and the other sites treat children or 
adults exclusively. Nine sites are public programmes funded 
largely by the DoH with strong research partnerships. One 
site is funded entirely by donor funding and another is a not-
for-profit hospital that receives a DoH subsidy and external 
funding for research projects. The study utilised data on adult 
patients from 8 sites, contributing between 642 and 17 835 
patients. Seven sites contributed data on paediatric patients, 
contributing between 264 and 2 226 patients. 
Treatment was free to all patients except those attending the 
state-subsidised hospital, who were charged a small inclusive 
monthly co-payment. Although most sites reported active 
follow-up of patients, follow-up of defaulting patients was 
generally limited owing to resource constraints. Patients were 
referred for treatment primarily from clinics, hospital wards 
and other medical facilities. Treatment readiness and patient 
preparation was fairly consistent across sites, involving a 
Table I. Characteristics of IeDEA-SA sites providing paediatric and adult ART in South Africa
   No. of         1st year          Tracing of 
Cohort            Level             patients        ART   Cost to        patients   Main source
            of care in dataset          Type of site         Patients    provision patient        LTFU    of referral to site
Empilweni          All levels 1 088 children   Public & research   Children &     2002  Free        No    Hospital wards
Clinic,               pregnant
Johannesburg             women
Free State            All levels  17 835 adults    Public          Adults &     2003  Free        Active tracing*    Clinics: primary
provincial roll-             children, mostly          in smaller   health care, TB, 
out programme             in combined           facilities   antenatal
              clinics
Gugulethu,         Primary 2 924 adults      Public & research    Adults &     2002  Free        Active tracing   Other medical
Cape Town  264 children          children,         facilities; clinics: 
              separate clinics       PMTCT, TB
Harriet Shezi      All levels 2 226 children   Public & research   Children only    2002  Free        Active tracing    Hospital wards
clinic, 
Johannesburg
Khayelitsha,       Primary 8 119 adults      Public & research    Adults &     2001  Free        Phone call only   Clinics: PMTCT,
Cape Town  662 children          children,         TB; other medical
              combined clinic       facilities
Masiphumelele,  Primary  642 adults         Public & research    Adults &    2003  Free         Active tracing   Clinics: PMTCT, 
Cape Town             children        STIs, TB; other
               medical facilities
McCord              Secondary 3 575 adults      Government-          Adults &     1999 (drug trial);  Small co-        Active tracing    Clinics: PMTCT, TB; 
Hospital,    415 children      subsidised, not-      children,     2000 (fee-paying); payment     other medical facilities
Durban             for-profit hospital   combined clinic  2004 onwards
           (PEPFAR funding)
Perinatal HIV     Tertiary 948 adults         Research          Adults &     2004 with some  Free        Active tracing    Wellness programme
Research Unit,              children,     trials <2004      for people with HIV
Johannesburg             combined clinics       in unit
Red Cross           Tertiary 859 children      Public & research   Children only    2001  Free        Active tracing    Hospital wards 
Children’s
Hospital, 
Cape Town
Themba Lethu,   Tertiary 9 250 adults      Public & research    Adults     2004  Free        Active tracing    Other medical facilities
Johannesburg
Tygerberg           Tertiary 1 504 adults      Public & research    Adults &     2004, with some  Free        Active tracing    Other medical
Hospital,    684 children          children,     trials <2004      facilities; clinics: 
Cape Town             separate clinics       PMTCT, TB
* Active tracing implies dedicated resources to undertake one or more of the following: telephone call, home follow-up, physician’s report and/or data linkage.
 LTFU = lost to follow-up;  PMTCT = prevention of mother-to-child-transmission programme;  TB = tuberculosis; STIs = sexually transmitted infections.
September 2009, Vol. 99, No. 9  SAMJ
ORIGINAL ARTICLES
656
baseline psychosocial assessment and 3 individual or group 
education sessions over 3 consecutive weeks. This process 
could be fast-tracked if the patient was pregnant or required 
immediate treatment for medical reasons. Patients were 
encouraged to disclose their HIV status and to have ‘treatment 
buddies’, and were referred to support groups where available. 
Characteristics of patients
The analysis included 45 383 adults and 6 198 children. The 
median age among adults was 35 years (interquartile range 
(IQR) 29.8 - 41.4) and among children 42.5 months (IQR 14.7 - 
82.5) (Table II). Of children, 21.2% (N=1 315) and 38.9% (N=2 
411) were aged <1 year and ≥5 years, respectively. Adult 
patients were predominantly female (67.6%, N=30 684). In 
contrast, the gender balance of children was even.
Among adults, the median CD4 cell count was 102 cells/µl 
(IQR 44 - 164). The median CD4 count was lower among 
adult males than females (86 v. 110 cells/µl, p<0.001). Among 
patients with baseline CD4 counts, the majority (89.4%,  
N=30 105) commenced therapy with CD4 cell counts below 
200/µl. A total of 9 363 adult patients (27.8%) initiated ART 
with CD4 counts <50 cells/µl. 
Among children, the median CD4% was 12.0% (IQR 7.0 - 
17.7), and 64.6% of paediatric patients (N=3 004) initiated 
therapy with CD4% <15%. In cohorts reporting WHO staging 
(28.1% of adults, N=12 763 and 66.5% of children, N=4 120) 
most patients had advanced HIV disease (WHO stage III or 
IV). 
In line with the national protocol, the majority of adult 
patients (87.7%, N=31 852) started on a regimen containing  
d4T and 3TC as the two nucleoside reverse transcriptase 
inhibitors (NRTIs); 68% (N=24 734) of adults and 53% (N=2 
846) of children started on a regimen containing EFV. Data on 
previous ART and prevention of mother-to-child transmission 
(PMTCT) exposure were limited. Where previous ART 
exposure was recorded, most adults (93%, N=22 062) and 
children (96%, N=4 100) were reportedly ART-naïve. In cohorts 
that reported PMTCT exposure, 13% (N=696) of women and 
25% of children (N=617) were known to have been exposed. 
Reliable data on tuberculosis (TB) at ART initiation were 
available from 2 adult and 2 paediatric cohorts. Among these 
adult patients, 3 722 (21%) had TB, while the proportion 
among children was slightly higher (32%, N=1 052). Of the 3 
adult cohorts that provided pregnancy data (N=8 828 female 
patients), 7% of female patients (N=633) were pregnant at ART 
initiation. In these cohorts, median CD4 count was higher 
among pregnant women than those who were not pregnant 
(150 v. 104, p<0.001) and higher among non-pregnant women 
than men (104 v. 80, p<0.001). 
Temporal trends
Table III shows temporal trends in enrolment, absolute 
and percentage CD4 and WHO stage. Over 5 years, patient 
numbers increased nearly 11-fold among adults (from 1 462 
to 15 628), and 3-fold among children (from 376 to 1 139). The 
majority of adults in this analysis (63%, N=28 643) started 
treatment in 2006 - 2007. Although paediatric enrolment 
appeared to drop substantially in 2007, this is probably because 
data from one of the largest paediatric cohorts were not 
available for the second half of 2007. 
There was an increase in overall adult baseline CD4 count, 
from a median of 67 cells/µl (IQR 23 - 134) in 2003 to 111 cells/
µl (IQR 49 - 171, p<0.001) in 2007, although the rate of increase 
declined over the years. Of all the paediatric patients, 3 787 
(61%) were <5 years of age. Among these patients, baseline 
CD4% was available for 76% (N=2 884) and median CD4% 
increased from 11.5% (IQR 7.1 - 18) in 2004 to 16.0% (IQR 11.0 - 
22.8, p<0.001) in 2007. In cohorts that provided data on staging, 
the proportion of adult patients in stage IV at enrolment fell 
from 50.3% (N=494) in 2003 to 26.9% (N=800) in 2007 (p<0.001). 
This was mirrored by an increase in median CD4 count in this 
group from 39 cells/µl (IQR 13 - 93) in 2003 to 89 cells/µl (IQR 
40 - 162, p<0.001) in 2007. Over time, the availability of baseline 
CD4 cell counts decreased from 72.2% to 64.8%.
Variation between sites
Tables IV and V demonstrate some degree of heterogeneity 
in patient characteristics between sites. Median adult age at 
enrolment ranged from 32 to 36 years. Baseline median CD4 
cell count ranged from 85 to 121 cells/µl. Within the paediatric 
sites, patients at two exclusively tertiary paediatric hospitals 
were younger, with a greater proportion <1 year, than those 
from other sites.
Discussion
IeDEA-SA: the South African collaborative cohort
This paper introduces the South African sites of IeDEA-SA, a 
dynamic collaboration that offers an excellent opportunity to 
provide information on the South African ART programme. It 
describes the baseline characteristics and temporal trends of 
the largest national cohort yet assembled of adults and children 
starting ART. The collaborative cohort is representative of 
patients accessing ART through the national programme in 
large urban centres, which constitute the largest part of this 
programme. It is constrained by the absence of cohorts from 
some provinces and by limited participation from rural sites. 
Many of the sites linked to research programmes may also 
have more capacity for monitoring than other sites in the 
national programme. The cohorts included in this collaboration 
have dramatically increased enrolment in line with the national 
roll-out of treatment, and demonstrate the same uniformity 
of clinical practice and patient preparation recommended in 
national guidelines.
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Table II. IeDEA South African cohort, patient characteristics at ART initiation: 45 383 adults and 6 198 children followed up in 
11 IeDEA-SA sites in South Africa, 2003 - 2007
      Adults (≥16 yrs)   Children
Characteristic     N=45 383    N=6 198
Age       N=45 383 (100%)   N=6 198 (100%)
   Adults (yrs), median (IQR)    35.0 (29.8 - 41.4)
   Children (mo.), median (IQR)       42.5 (14.7 - 82.5)
   Age categories, N (%)
     <12 mo.         1 315 (21.2)
     12 - 23 mo.          891 (14.4)
     24 - 59 mo.          1 581 (25.5)
     ≥60 mo.          2 411 (38.9) 
Gender      N=45 383 (100%)   N=6 198 (100%)
   Female, N  (%)     30 684 (67.6)   3 051 (49.2)
Absolute CD4 cell count (cells/µl)   N=33 672 (75.2%)*   N=4 900 (79.1%)
   All adults, median (IQR)    102 (44 - 164)
      Men      86 (34 - 150)
      Women     110 (50 - 169)
   CD4 cell count categories, N (%)
      <50      9 363 (27.8)
      50 - 199     20 742 (61.6)
      ≥200      3 567 (10.6)
All children, median (IQR)        391 (172 - 730)
CD4%      N/A    N=4 648 (75.0)†
   Median (IQR)           12.0 (7.0 - 17.7)
   CD4% categories, N (%) 
      <15%          3 004 (64.6)
      15 - 19%         760 (16.4)
      ≥20%          884 (19.0)
WHO stage, N (%)     N=12 763 (28.1)‡   N=4 120 (66.5)§
   I       1 134 (8.9)   270 (6.5)
   II      1 512 (11.9)   752 (18.3)
   III       6 118 (47.9)   
   IV      3 999 (31.3)   3 098 (75.2)¶
HIV RNA level (log10 copies/ml)    N=14 955 (33.0)
®   N=4 116 (66.4)
   Median (IQR)      4.89 (4.34 - 5.41)   5.3 (4.7 - 5.9)
1st-line ART regimen used, N (%)   N=36 319 (81.1)**   N=5 331 (86.0)
   d4T+3TC+EFV     23 568 (64.9)   2 692 (50.5)
   d4T+3TC+NVP     8 284 (22.8)   93 (1.7)
   AZT+3TC+NVP     1 350 (3.7)   74 (1.4)
   AZT+3TC+EFV     1 166 (3.2)   154 (2.9)
   d4T+3TC+KLT††         1 343 (25.2)
   d4T+3TC+RTV         268 (5.0)
   Other      1 951 (5.4)   707 (13.3)
Previous ART exposure, N (%)   N=23 735 (53.0) ‡‡   N=4 262 (68.8) 
   ART exposure     1 673 (7.1)   162 (3.8)
PMTCT exposure, N (%)     N=5 526 (12.3)§§   N=2 430 (39.2)¶¶
   Known exposed women/children   696 (12.6)    617 (25.4)
TB at ART initiation, N (%)     N=17 369 (38.8)®®   N=3 305 (53.3)
   Yes      3 722 (21.4)   1 052 (31.8)
Pregnant at ART initiation, N (%)   N=8 828***    N/A†††
   Yes      633 (7.2) 
*Data from all cohorts; CD4 not always provided in dataset.  
† Data from 6 paediatric cohorts.    ‡‡Data from 3 cohorts.
‡Includes data from 4 cohorts.     §§Data from 2 cohorts.
§Data from all cohorts; WHO stage not always provided in dataset.  ¶¶ Data from 4 cohorts.
¶ Stages III & IV combined for children.    ®®Data from 2 cohorts.
®Data from all cohorts; viral load not always provided in dataset.  ***Data on female patients from 3 cohorts.
**Only listed those regimens prescribed to >4% of adult patients.  †††Data not provided in paediatric datasets.
††Includes 209 children on ritonavir and Kaletra.   IQR = interquartile range; TB = tuberculosis.
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Evidence of national scale-up
The massive increase in enrolment over time, especially over 
the last 2 years, provides strong evidence of the successful 
scale-up of ART in South Africa. Patients are enrolling with 
less advanced disease in urban sites: among patients with a 
baseline CD4 count, there has been a trend towards higher CD4 
count at initiation, and the proportion of patients in stage IV 
has decreased.
Late diagnosis and initiation of treatment
Patients in this combined cohort were still being diagnosed 
and started on ART later than recommended in national and 
international guidelines, increasing their risk of early mortality 
on treatment.6 In our collaborative cohort, more than 25% of 
patients started with a CD4 count <50 cells/µl, and similarly 
with stage IV disease. Earlier diagnosis and initiation of ART 
would reduce the risk of morbidity and mortality among these 
patients, especially for men, who present with more advanced 
HIV disease and appear to be disadvantaged in their access to 
treatment.7,8
Children
The paediatric component of this collaboration is to our 
knowledge the largest national cohort of children on ART in 
the world. While the successful enrolment of so many children 
on ART is encouraging, limited success in preventing vertical 
transmission of HIV remains a major concern.
In addition, children also started ART later than is now 
internationally recommended.9 South African data have 
demonstrated the high risk of disease progression and 
mortality in the first year of life.10,11 The low proportion 
enrolled in the first year of life in this cohort, and high 
Table III. IeDEA South African cohort: temporal changes
                  p-value  
Year of ART initiation  ≤2003          2004 2005         2006  2007        for trend   Combined
Patients enrolled, N (%)
   Adults     1 462 (3.2)         5 340 (11.8) 9 938 (21.9)       13 015 (28.7)     15 628 (34.4)                    45 383 (100)
   Children    376 (6.0)          1 094 (17.7) 1 849 (29.8)       1 740 (28.1)       1 139 (18.4)                      6 198 (100)
Baseline CD4 (cells/µl)
   All adults          N   1 055          4 597 8 476          9 417 10 127                         33 672 
           Med. (IQR) 67 (23 - 134)      86 (38 - 147) 101 (43 - 159)    105 (45 - 168) 111 (49 - 171)     <0.001    102 (44 - 164)
Men           N   341          1 433 2 726          3 177 3 397          11 074
           Med. (IQR) 54 (18 - 123)      74 (33 - 138) 87 (33 - 149)      88 (34 - 154) 93 (36 - 154)       <0.001    86 (34 - 150)
Women          N  714          3 164 5 750          6 240 6 730          22 598 
           Med. (IQR) 74 (26 - 138)      91 (41 - 150) 107 (48 - 164)    115 (52 - 174) 120 (56 - 179)     <0.001    110 (50 - 169)
Children <5 yrs          N             638*  1 160          1 091 684          3 787
   CD4%           Med. (IQR)            11.5 (7.1 - 18) 12.2 (8.1 - 17.6) 14.0 (9.4 - 20)   16.0 (11.0 - 22.8) <0.001    13.0 (8.7 - 19)
Adults in stage IV          N (%) 494 (50.3)          708 (38.5) 998 (31.3)         999 (26.5) 800 (26.9)          3 999 (33.3)
           Med. CD4, 
           cells/µl (IQR) 39 (13 - 93)        54 (20 - 115) 68 (24 - 138)     74 (29 - 147) 89 (40 - 162)       <0.001    66 (25 - 236)
Availability of laboratory
tests at baseline          CD4 cell  72.2%          86.1% 85.3%         72.4% 64.8%          74.2%
           count
           CD4% <5 yrs           74.9% 77.2%         78.6% 71.9%          76.2%
*In this table, all children <5 yrs before 2004 were combined owing to low numbers and erratic enrolment in different research sites.
Med. = median; IQR = interquartile range.
Table IV. Adult patient characteristics by cohort
              Free State                 Masi-                Themba
Cohort              province       Gugulethu   Khayelitsha         phumelele         McCord  PHRU              Lethu      Tygerberg
Adults enrolled, N (%)        17 835 (39.3)       2 924 (6.4)   8 119 (17.9)          642 (1.4)        3 575 (7.9)  948 (2.1)             9 836 (21.7)        1 504 (3.3)
Age (yrs), med. (IQR)          36 (31 - 43)         33 (29 - 39)   33 (28 - 39)          32 (27 - 37)         35 (30 - 41)  34 (30 - 40)          35 (30 - 41)        34 (29 - 41)
CD4 cell count             114 (55 - 167)      101 (48 - 158)   101 (45 - 165)      121 (46 - 193)      85 (31 - 152)       108 (43 - 171)       88 (32 - 158)      116 (52 - 174)
(cells/µl), med. (IQR)
Patients with CD4              2 175 (22.1)         631 (25.4)   1 932 (27.3)         152 (25.8)        1 025 (35.1)  197 (25.7)             2 966 (33.7)       284 (23.9)
<50 cells/µl, N (%)
med. = median; IQR = interquartile range.
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numbers of children with advanced disease, suggest massive 
under-diagnosis and missed treatment opportunities, and an 
enormous hidden burden of morbidity and mortality among 
children.
First-line regimen
Unlike many countries in southern Africa, in which the first-
line regimen is a fixed-dose combination of d4T, 3TC and NVP, 
EFV use predominates in adults on treatment in South Africa 
in spite of the higher cost of EFV-based regimens. Analyses 
in South Africa have, however, reported inferior virological 
outcomes in patients on NVP-containing compared with 
EFV-containing regimens.12,13 For many adults starting ART, 
concomitant TB at the time of starting ART precludes the use of 
NVP. In addition, the greater toxicity profile of NVP compared 
with EFV has discouraged many clinicians from using it as 
first-line treatment. The use of protease inhibitors (PIs) versus 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
in children in this analysis is in line with the proportions of 
children starting ART above and below 3 years of age.
Data challenges and the need for sentinel 
surveillance
Although South Africa has implemented the largest treatment 
programme in the world, the ability to monitor the programme 
closely has not kept pace with this expansion.2 The lack of 
complete data on baseline characteristics in these cohorts – 
among the best-monitored ART programmes nationally – 
provides insight into the pressures facing the public health 
system.
Numerous challenges face cohort analysis of ART 
programmes in developing countries, chiefly the need to 
balance service provision and the collection of good-quality 
data in the face of rapidly increasing patient numbers. An 
11-fold increase in patients over 5 years is bound to result in 
a corresponding decrease in data quality unless substantial 
resources are provided to support monitoring systems. 
For health care workers, providing access to clinical care 
is – and should be – the priority. It is therefore essential to 
find ways to avoid overwhelming health care providers and 
prioritising monitoring over service provision.14 Establishing 
selected, representative sentinel surveillance sites may 
facilitate the collection of good-quality individual data on a 
subset of patients in the national programme, thus freeing 
most government sites to continue with simplified aggregate 
reporting.15
Conclusion
The South African cohorts participating in IeDEA-SA provide a 
unique opportunity to undertake analyses of the national ART 
programme based on individual patient data, to complement 
routine monitoring. This analysis demonstrates the massive 
scale-up in recent years and the improvement in the level 
of disease severity at ART initiation. Earlier diagnosis and 
enrolment of patients, particularly children and men, need to 
be prioritised. A solid investment in representative sentinel 
surveillance could support a context-appropriate national ART 
monitoring system.
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med. = median; IQR = interquartile range.
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